Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
82 studies found for:    "Rubella"
Show Display Options
Rank Status Study
21 Withdrawn Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
Conditions: Mumps;   Rubella;   Measles;   Varicella
Interventions: Biological: Priorix-Tetra™;   Other: Safety data collection
22 Completed Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age
Conditions: Rubella;   Measles;   Mumps
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
23 Active, not recruiting Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR
Conditions: Measles;   Rubella;   Mumps
Intervention: Biological: Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®
24 Completed Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Conditions: Varicella;   Rubella;   Measles;   Mumps
Interventions: Biological: MeMuRu-OKA (study vacc);   Biological: MMR, Varicella vacc (control)
25 Completed Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Conditions: Mumps;   Rubella;   Measles;   Varicella
Interventions: Biological: MeMuRu-OKA (study vac);   Biological: MMR, Varicella vacc (control)
26 Recruiting Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine
Conditions: Encephalitis, Japanese;   Measles;   Mumps;   Rubella
Interventions: Biological: CD-JEV;   Biological: MMR
27 Completed Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)
Conditions: Measles;   Mumps;   Rubella;   Varicella
Intervention: Biological: V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
28 Completed
Has Results
Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMRV (AMP);   Biological: MMRV (2006 process)
29 Completed
Has Results
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: GSK Biological's investigational vaccine 209762;   Biological: M-M-R® II (Merck and Co);   Biological: Varivax®;   Biological: Havrix®;   Biological: Prevnar®
30 Completed Measles, Mumps, and Rubella (MMR) Immunity in College Students
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR vaccine
31 Completed Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
Condition: Influenza
Intervention: Biological: CAIV-T
32 Completed Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children
Condition: Influenza
Interventions: Biological: FluMist;   Other: Placebo
33 Terminated Immune Responses to Two Dose Varivax +/- MMR-II
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR-II;   Biological: Pro-Quad;   Biological: Varivax
34 Completed ProQuad® rHA Safety
Conditions: Measles;   Mumps;   Rubella;   Varicella
Intervention: Biological: ProQuad® manufactured with rHA
35 Completed Making Decisions About the Measles-Mumps-Rubella Vaccine
Conditions: Measles;   Mumps;   Rubella;   MMR Vaccination
Intervention: Other: Behavioral: Computer-based tailoring system
36 Completed Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis
Condition: Arthritis, Juvenile Rheumatoid
Intervention: Biological: Measles, Mumps, Rubella vaccination
37 Completed Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox
Condition: Varicella
Interventions: Biological: Priorix-tetra™;   Biological: Priorix™;   Biological: Varilrix™
38 Not yet recruiting Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Condition: Malaria Vaccines
Interventions: Dietary Supplement: Vitamin A;   Biological: Candidate Plasmodium falciparum malaria vaccine;   Biological: MR-Vac;   Biological: Stamaril
39 Completed
Has Results
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children
Condition: Hepatitis A
Interventions: Biological: Havrix®;   Biological: M-M-R®II;   Biological: VARIVAX®
40 Completed Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
Conditions: Measles;   Mumps;   Rubella;   Hepatitis A
Interventions: Biological: Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella;   Biological: Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.